Peripartum Cardiomyopathy
12
2
2
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
17%
2 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (12)
PPCM Observational Study (Peripartum Cardiomyopathy)
Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study.
Diastolic Dysfunction PPCM in Patients With Documented Left Ventricular Systolic Function Recovery
Creation of a Multicenter National Registry for Peripartum Cardiomyopathy.
Bromocriptine in the Treatment of Peripartum Cardiomyopathy
Irisin Expression and Gene Polymorphism With Peripartum Cardiomyopathy.
Peripartum Cardiomyopathy in Nigeria Registry
"Treatment Use of ECMO In Pregnancy or Peripartum Patient."
Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy
NT-proBNP Levels and Obesity in Pregnancy
Taurine in Peripartum Cardiomyopathy
A Registry of Peripartum Cardiomyopathy in Turkey